RBC Life Sciences Profit Margin

The latest profit margin for RBCL is -2.93% as of September 2017. That compares with -2.94% in the prior-year period — up 0.6% year over year. That is below the sector sector average of 13.16%. Investors often review this figure alongside RBC Life Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, RBCL's profit margin moved from -2.94% to -2.93% — a 0.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in RBC Life Sciences's valuation or profitability profile.

Against its sector companies, RBCL currently prints -2.93% for profit margin, while the sector average sits near 13.16%. That is roughly 122.2% below the sector mean. Large gaps often invite a closer look at RBC Life Sciences's growth, margins, and balance sheet.

Profit Margin shows how effectively RBC Life Sciences converts resources into returns. At -2.93%, RBCL may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2.94% in the prior-year period — up 0.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RBCL's profit margin (-2.93%), review year-over-year change from -2.94%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.